Year: 2024
Type: article
Abstract: Lutetium-177 prostate-specific membrane antigen (Lu-PSMA) is a peptide receptor radionuclide therapy recently approved by the US Food and Drug Administration and the European Medicines Agency, for PSMA-positive metastatic castration resistant prostate cancer.1 The recommended dose is 7.4 gigabecquerels i.v. every 6 weeks for up to 6 doses, until disease progression or unacceptable toxicity.2 However extended therapy has not been associated with increase in grade 3 to 4 toxicity.3 This treatment targets the PSMA-expressing cells to deliver radiotherapy on specific tissues.
Source: Kidney International Reports
Institutions: Centre Hospitalier Universitaire de Tours, Inserm, Aix-Marseille Université, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Hôpital de la Conception, Centre Européen de Recherche en Imagerie Médicale, Centre de Recherche en CardioVasculaire et Nutrition, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay, Assistance Publique – Hôpitaux de Paris, Hôpital Ambroise-Paré, Université de Tours, methodS in Patient-centered outcomes and HEalth ResEarch, Université de Nantes, Nantes Université
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,800
OpenAlex ID: W4404337573